

## Concerns due to Patenting of Secondary Drugs

### What is the issue?

\n\n

\n

- Pharmaceutical industry has provisions to ban anti-evergreening during secondary patenting of drugs.

\n

- Indian Patent Office (IPO) abstains from following such provisions and has been granting more secondary patents.

\n

\n\n

### What is Evergreening in intellectual property?

\n\n

\n

- The first step that pharmaceutical corporations take on discovering an entirely new drug is to secure intellectual property rights for it in the form of a patent.

\n

- A primary patent covering a new molecular/chemical entity, rewards innovation with a free reign over the marketplace for a period of 20 years, which is the term of the patent.

\n

- Once this expires, generics enter the fray with cheaper versions and compete in this lucrative marketplace to drive prices down.

\n

- This entails the pharma companies to go through an entire cycle of discovery, clinical trials, marketing and distribution, replete with the risk of failure at every step.

\n

- To resolve such issues Innovators seek to reset the 20-year time frame by subsequently filing patents that are minor variants of the parent compound, called secondary patents.

\n

- This practice, known as evergreening which allows a prolonged monopoly that unfairly denies the public access to medicines at equitable prices.

\n

\n\n

## What is Patent Act in India?

\n\n

\n

- The present Patents Act, 1970 came into force in the year 1972, amending and consolidating the existing law relating to Patents in India.

\n

- India has been at the forefront of developing an alternative model of patent law which many developing countries have since emulated.

\n

\n\n

\n

- The IPO incorporated following anti-evergreening provisions into the Patents Act

\n

\n\n

\n

1. **Section 3(d)** - Covers combinations and other derivatives of known substance.

\n

2. **Section 3(e)** - Covers substance obtained by a mere admixture resulting only in the aggregation of the properties of the components or a process for producing such substance.

\n

3. **Section 3(i)** - Excludes methods of treatments from the purview of patent protection.

\n

\n\n

\n

- These provisions were introduced to restrict patentability of a host of secondary patents, which were basically alternative forms of already existing patented drugs aimed to further extend their term of protection.

\n

- In case of objections in these provisions, the law requires the patent applicants to submit efficacy data for the former drug and demonstrate synergism for the later.

\n

\n\n

## What are the existing concerns in patenting of drugs?

\n\n

\n

- In recent times, the IPO has been focussing on granting patents expeditiously and reducing the backlog of pending applications.

\n

- Despite high standards for granting patents, the IPO has been granting patents for merely tweaks in drugs.

\n

- Due to this the IPO is also operating at an error rate of more than 70% corresponding to all secondary patents granted.

\n

- Stringent rules are being bypassed by the patent applicants which allows the IPO to grant patents only for new form of substances and not combination of known substances.

\n

- Thus the application of law with regard to anti-evergreening, by IPO has been far from satisfactory.

\n

\n\n

\n\n

**Source: The Hindu**

\n\n

\n

